首页> 美国卫生研究院文献>Drug Design Development and Therapy >Synthesis anti-inflammatory analgesic COX1/2-inhibitory activity and molecular docking studies of hybrid pyrazole analogues
【2h】

Synthesis anti-inflammatory analgesic COX1/2-inhibitory activity and molecular docking studies of hybrid pyrazole analogues

机译:杂吡唑类似物的合成抗炎止痛COX1 / 2抑制活性和分子对接研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This article reports on the design, synthesis, and pharmacological activity of a new series of hybrid pyrazole analogues: >5a–>5u. Among the series >5a–>5u, the compounds >5u and >5s exhibited potent anti-inflammatory activity of 80.63% and 78.09% and inhibition of 80.87% and 76.56% compared with the standard drug ibuprofen, which showed 81.32% and 79.23% inhibition after 3 and 4 hours, respectively. On the basis of in vivo studies, 12 compounds were selected for assessment of their in vitro inhibitory action against COX1/2 and TNFα. The compounds >5u and >5s showed high COX2-inhibitory activity, with half-maximal inhibitory concentrations of 1.79 and 2.51 μM and selectivity index values of 72.73 and 65.75, respectively, comparable to celecoxib (selectivity index =78.06). These selected compounds were also tested for TNFα, cytotoxicity, and ulcerogenicity. Docking studies were also carried out to determine possible interactions of the potent compounds (>5u and >5s), which also showed high docking scores of −12.907 and −12.24 compared to celecoxib, with a −9.924 docking score. These selective COX2 inhibitors were docked into the active site of COX2, and showed the same orientation and binding mode to that of celecoxib (selective COX2 inhibitor). Docking studies also showed that the SO2NH2 of >5u and >5s is inserted deep inside the selective pocket of the COX2-active site and formed a hydrogen-bond interaction with His90, Arg513, Phe518, Ser353, Gln192, and Ile517, which was further validated by superimposed docked pose with celecoxib.
机译:本文报道了一系列新的杂吡唑类似物> 5a – > 5u 的设计,合成和药理活性。在> 5a – > 5u 系列中,化合物> 5u 和> 5s 表现出有效的抗炎活性,为80.63%,与标准药物布洛芬相比,抑制作用分别为78.09%和80.87%和76.56%,布洛芬在3和4小时后分别显示81.32%和79.23%。在体内研究的基础上,选择了12种化合物以评估其对COX1 / 2和TNFα的体外抑制作用。化合物> 5u 和> 5s 具有较高的COX2抑制活性,半数抑制浓度分别为1.79和2.51μM,选择性指数分别为72.73和65.75,与塞来昔布(选择性指数= 78.06)。还测试了这些选定的化合物的TNFα,细胞毒性和致溃疡性。还进行了对接研究,以确定强效化合物(> 5u 和> 5s )之间的可能相互作用,与塞来昔布相比,它们的对接分数也很高,分别为-12.907和-12.24,对接得分为−9.924。这些选择性的COX2抑制剂停靠在COX2的活性位点,并显示出与celecoxib(选择性COX2抑制剂)相同的方向和结合方式。对接研究还表明,> 5u 和> 5s 的SO2NH2插入了COX2活性位点的选择性口袋深处,并与His90,Arg513, Phe518,Ser353,Gln192和Ile517,并通过塞来昔布的对接姿势叠加进行了进一步验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号